Erika Roberson

Director of UAB’s Alzheimer’s Disease Research Center and UAB’s Center for Neurodegeneration and Experimental Therapeutics · University of Alabama Hospital

Credentials: · · · · ·

History

University of Alabama Hospital
Present
UAB’s Alzheimer’s Disease Research Center and UAB’s Center for Neurodegeneration and Experimental Therapeutics · University of Alabama Hospital
Present
University of Alabama Hospital
Present

Neurology
1999–2003
Baylor College of Medicine
1995–1999

Research

Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing
Systematic review or meta-analysis · Nature Genetics · 2019 · 2,420 citations
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model
Science · 2007 · First of 9 authors · Corresponding · 1,584 citations
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
Systematic review or meta-analysis · Nature Genetics · 2011 · 1,577 citations

AB
Adam Boxer
39 papers
Bradley Boeve
35 papers
Neill Graff-Radford
35 papers
HR
Howie Rosen
32 papers
Bruce Miller
31 papers
EH
Edward Huey
29 papers
Irene Litvan
29 papers
Mario Mendez
27 papers
Bradford Dickerson
26 papers
Douglas Galasko
26 papers
Nupur Ghoshal
26 papers
Kimiko Domoto-Reilly
25 papers

Grants

UAB Alzheimer's Disease Research Center
National Institute on Aging · P30
Contact PI · $12.8M · University of Alabama at Birmingham
2024–2029
UAB Training Program in Neurodegeneration
National Institute of Neurological Disorders and Stroke · T32
Contact PI · $873.1K · University of Alabama at Birmingham
2017–2027
Circadian Changes in Network Excitability and Alzheimer Disease Pathogenesis
National Institute on Aging · R01
Contact PI · $3.9M · University of Alabama at Birmingham
2021–2027
UAB Alzheimer's Disease Research Center
National Institute on Aging · P20
Contact PI · $3.3M · University of Alabama at Birmingham
2020–2024

Clinical trials

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Site PI · Recruiting · Phase 2, Phase 3
Washington University School of Medicine
2024–2034
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Site PI · Recruiting · Phase 2, Phase 3
Washington University School of Medicine
2024–2034
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Site PI · Recruiting
Mayo Clinic
2020–2030